ArticleIrish journal of medical science2026
Evaluation of CXCL12 levels in diabetic and non-diabetic chronic kidney disease.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) constitutes a significant global health challenge due to its association with elevated morbidity and mortality rates. Diabetic nephropathy is a primary contributor to CKD progression, predominantly resulting from persistent inflammatory and fibrotic processes. CXCL12 is a multifunctional chemokine that has been implicated in renal pathology through context-dependent protective and deleterious effects.
aimThis study aimed to investigate circulating CXCL12 and CXCR4 levels in patients with diabetic nephropathy, and non-diabetic nephropathy, and to evaluate their association with disease severity.
methodsThis study included 177 participants comprising 60 patients with diabetic nephropathy, 57 patients with non-diabetic nephropathy, and 60 healthy controls. Plasma CXCL12 and CXCR4 concentrations were measured using ELISA method. The Kruskal-Wallis test and subsequent post hoc analyses were used to compare groups. ROC curve analysis evaluated the diagnostic value of the biomarkers. Also, binary logistic regression identified independent predictors of CKD.
resultsCXCL12 concentrations differed significantly between study groups and were highest in patients with diabetic nephropathy. CXCL12 levels increased with advancing CKD stage in the overall cohort. While no significant stage-related variation was observed in diabetic nephropathy, a pronounced stage-dependent increase was evident in non-diabetic nephropathy. CXCR4 levels showed minimal variation and weaker associations with disease stage. CXCL12 demonstrated good discriminatory performance and independently predicted CKD presence.
conclusionElevated CXCL12 levels are strongly associated with CKD irrespective of underlying etiology and may represent a valuable biomarker for disease detection and progression, particularly in non-diabetic CKD.
Indexed as
Identifiers
42295602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.